$NRIX SEC Filings

Received 1,452 shares by exercise or conversion ($2.7K) · Sold 1,452 shares ($36.3K)

Received 22,583 shares by exercise or conversion ($42K) · Sold 22,583 shares ($529K)

Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL

Received 5,786 shares by exercise or conversion ($50.5K) · Sold 5,786 shares ($134K)

Received 5,787 shares by exercise or conversion ($50.5K) · Sold 5,787 shares ($149K)

Received 1,452 shares by exercise or conversion ($2.7K) · Sold 1,452 shares ($37K)

Received 4,356 shares by exercise or conversion ($8.1K) · Sold 4,356 shares ($109K)

Sold 4,111 shares ($100K)

Sold 4,761 shares ($116K)